VN-0200 + Placebo

Phase 1Completed

2 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Respiratory Syncytial Virus Infections

Conditions

Respiratory Syncytial Virus Infections

Trial Timeline

Jun 11, 2021 → Dec 16, 2021

NCT ID

NCT04914520

About VN-0200 + Placebo

VN-0200 + Placebo is a phase 1 stage product being developed by Daiichi Sankyo for Respiratory Syncytial Virus Infections. The current trial status is completed. This product is registered under clinical trial identifier NCT04914520. Target conditions include Respiratory Syncytial Virus Infections.

What happened to similar drugs?

10 of 20 similar drugs in Respiratory Syncytial Virus Infections were approved

Approved (10) Terminated (3) Active (9)

✅Zopapogene imadenovec (Zopa)PrecigenApproved

✅YMC026 + PlaceboYuhanApproved

✅Montelukast + PlaceboMerckApproved

✅Sugammadex 100 MG/ML [Bridion]MerckApproved

✅diclofenac potassium + nimesulideNovartisApproved

✅Bacterial Lysates + placeboSanofiApproved

✅Telithromycin + AzithromycinSanofiApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04914520	Phase 1	Completed	Jun 11, 2021	Dec 16, 2021	Respiratory Syncytial Virus Infections

Competing Products

20 competing products in Respiratory Syncytial Virus Infections

See all competitors

Product	Company	Stage	Hype Score
mRNA-1273	Moderna	Phase 1	0
mRNA-1345	Moderna	Phase 3	0
mRNA-1345	Moderna	Phase 1	0
mRNA-1345	Moderna	Phase 2	0
mRNA-1345	Moderna	Phase 2	0
mRNA-1345	Moderna	Phase 3	0
mRNA-1345	Moderna	Phase 3	0
mRNA-1345	Moderna	Preclinical	0
mRNA-1345	Moderna	Phase 3	0
mRNA-1345	Moderna	Phase 3	0
mRNA-1345	Moderna	Phase 1	0
Zopapogene imadenovec (Zopa)	Precigen	Approved	44
PRGN-2012 - Phase I; Dose Level 1 + PRGN-2012 - Phase I; Dose Level 2 + PRGN-2012 - Phase II; Dose Level 2	Precigen	Phase 1/2	30
agenT-797	MiNK Therapeutics	Phase 1	19
YMC026 + Placebo	Yuhan	Approved	43
VN-0200	Daiichi Sankyo	Phase 2	35
Isavuconazonium Injection [Cresemba] + Placebo	Astellas Pharma	Phase 3	32
S-337395 + Placebo	Shionogi	Phase 2	42
Sivelestat	Eli Lilly	Phase 1/2	32
Itolizumab IV infusion + Best supportive care (BSC)	Biocon	Phase 2	35